The Chinese Sinovac anti-Covid vaccine, on which the European drug agency Ema has announced the start of the cyclical review procedure, is “a conventional vaccine, which uses the whole virus inactivated, no more and no less than what we do. every year against the flu “. And in this mechanism there is a “potential advantage, already described in some scientific papers”, which concerns a possible ‘extra gear’ towards the mutations that Sars-CoV-2, like all viruses, undergoes. This was highlighted by Roberto Cauda, director of the Infectious Diseases Operating Unit of the Gemelli Polyclinic in Rome, who spoke at ‘Agorà’ on Rai3. Read also The expert recalls that the Spike protein, the ‘hook’ used by the pandemic coronavirus to attack target cells, is the “privileged component actually used in the vast majority of anti-Covid vaccines” developed so far. “If Spike undergoes mutations, which even today are not so important in reducing the effectiveness of vaccines currently available, using a ‘whole’ vaccine” like the Chinese one “you don’t just have an” organism “response to Spike, but also towards other components of the virus. So this could, but the conditional is a must and must be emphasized – points out the infectious disease specialist – to give greater protection “. As for the effectiveness of the Chinese product, which for example in Chile has been estimated at 54% after the second dose, Cauda points out that “a vaccine is considered effective by the World Health Organization if it exceeds 50% effectiveness”, even if “then we must always agree on the meaning of efficacy and protection, two slightly different concepts “. “I add that this vaccine has also been used in other countries, with higher results than those indicated in Chile”, continues the Gemelli expert who invites you to rely on EMA: “EMA is an independent international body of great authority , and during the rolling review he will see what is all the data “so he can decide based on the evidence.